King's College London

Research portal

Cancer and Risk of COVID-19 Through a General Community Survey

Research output: Contribution to journalArticlepeer-review

COPE Consortium

Original languageEnglish
Article numberONCO13497
JournalONCOLOGIST
Volume26
Issue number1
Early online date26 Aug 2020
DOIs
E-pub ahead of print26 Aug 2020
PublishedJan 2021

Bibliographical note

Funding Information: We thank the more than 3 million contributing citizen scientists who have downloaded the COVID Symptom Study, including participants of cohort studies within the COronavirus Pandemic Epidemiology (COPE) Consortium. We also thank the investigators of the cohort studies enrolled in the COPE Consortium; the MGH Clinical and Translational Epidemiology Unit Clinical Research Coordination team; Sophie Papa, Paul Nathan, and Heather Shaw for development of cancer-related questions; the staff of Zoe Global Ltd for providing technical support for the app; and Stand Up to Cancer for their assistance in media and social media outreach. Zoe provided in-kind support for all aspects of building, running, and supporting the app and service to all users worldwide. King's College of London investigators (K.A.L., C.J.S., T.D.S.) were supported by the Wellcome Trust and EPSRC (WT212904/Z/18/Z, WT203148/Z/16/Z, T213038/Z/18/Z), the NIHR GSTT/KCL Biomedical Research Centre, MRC/BHF (MR/M016560/1), and the Alzheimer's Society (AS-JF-17-011). K.A.L. was supported by the Seerave Foundation. A.T.C. is the Stuart and Suzanne Steele MGH Research Scholar and Stand Up to Cancer scientist. The Massachusetts Consortium on Pathogen Readiness (MassCPR) and Mark and Lisa Schwartz also supported MGH investigators (W.M., D.R.S., D.A.D., L.H.N., C.G.G., A.D.J., S.K., C.H.L., R.M., M.S., A.T.C.). Support was also received from the Swedish Foundation for Strategic Research (LUDC-IRC 15-0067), the Swedish Heart-Lung Foundation, and the Swedish research Council. In the U.K., the App Ethics has been approved by KCL ethics Committee REMAS ID 18210, review reference LRS-19/20-18210, and all subscribers provided consent. In the U.S, ethics approval was provided by the Human Research Committee at Mass General Brigham. In Sweden, ethics approval for the study was provided by the central ethics committee (DNR 2020-01803). Data collected in the app are being shared with other health researchers through the NHS-funded Health Data Research U.K. (HDRUK)/SAIL consortium, housed in the U.K. Secure e-Research Platform (UKSeRP) in Swansea. Anonymized data collected by the symptom tracker app can be shared with bonafide researchers via HDRUK, provided the request is made according to their protocols and is in the public interest (see https://healthdatagateway.org/detail/9b604483-9cdc-41b2-b82c-14ee3dd705f6). U.S. investigators are encouraged to coordinate data requests through the COPE Consortium (www.monganinstitute.org/cope-consortium). Data updates can be found at https://covid.joinzoe.com. Funding Information: We thank the more than 3 million contributing citizen scientists who have downloaded the COVID Symptom Study, including participants of cohort studies within the COronavirus Pandemic Epidemiology (COPE) Consortium. We also thank the investigators of the cohort studies enrolled in the COPE Consortium; the MGH Clinical and Translational Epidemiology Unit Clinical Research Coordination team; Sophie Papa, Paul Nathan, and Heather Shaw for development of cancer‐related questions; the staff of Zoe Global Ltd for providing technical support for the app; and Stand Up to Cancer for their assistance in media and social media outreach. Zoe provided in‐kind support for all aspects of building, running, and supporting the app and service to all users worldwide. King's College of London investigators (K.A.L., C.J.S., T.D.S.) were supported by the Wellcome Trust and EPSRC (WT212904/Z/18/Z, WT203148/Z/16/Z, T213038/Z/18/Z), the NIHR GSTT/KCL Biomedical Research Centre, MRC/BHF (MR/M016560/1), and the Alzheimer's Society (AS‐JF‐17‐011). K.A.L. was supported by the Seerave Foundation. A.T.C. is the Stuart and Suzanne Steele MGH Research Scholar and Stand Up to Cancer scientist. The Massachusetts Consortium on Pathogen Readiness (MassCPR) and Mark and Lisa Schwartz also supported MGH investigators (W.M., D.R.S., D.A.D., L.H.N., C.G.G., A.D.J., S.K., C.H.L., R.M., M.S., A.T.C.). Support was also received from the Swedish Foundation for Strategic Research (LUDC‐IRC 15‐0067), the Swedish Heart‐Lung Foundation, and the Swedish research Council. In the U.K., the App Ethics has been approved by KCL ethics Committee REMAS ID 18210, review reference LRS‐19/20‐18210, and all subscribers provided consent. In the U.S, ethics approval was provided by the Human Research Committee at Mass General Brigham. In Sweden, ethics approval for the study was provided by the central ethics committee (DNR 2020‐01803). Data collected in the app are being shared with other health researchers through the NHS‐funded Health Data Research U.K. (HDRUK)/SAIL consortium, housed in the U.K. Secure e‐Research Platform (UKSeRP) in Swansea. Anonymized data collected by the symptom tracker app can be shared with bonafide researchers via HDRUK, provided the request is made according to their protocols and is in the public interest (see https://healthdatagateway.org/detail/9b604483‐9cdc‐41b2‐b82c‐14ee3dd705f6 ). U.S. investigators are encouraged to coordinate data requests through the COPE Consortium ( www.monganinstitute.org/cope‐consortium ). Data updates can be found at https://covid.joinzoe.com . Publisher Copyright: © 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

King's Authors

Abstract

Individuals with cancer may be at high risk for coronavirus disease 2019 (COVID-19) and adverse outcomes. However, evidence from large population-based studies examining whether cancer and cancer-related therapy exacerbates the risk of COVID-19 infection is still limited. Data were collected from the COVID Symptom Study smartphone application since March 29 through May 8, 2020. Among 23,266 participants with cancer and 1,784,293 without cancer, we documented 10,404 reports of a positive COVID-19 test. Compared with participants without cancer, those living with cancer had a 60% increased risk of a positive COVID-19 test. Among patients with cancer, current treatment with chemotherapy or immunotherapy was associated with a 2.2-fold increased risk of a positive test. The association between cancer and COVID-19 infection was stronger among participants >65 years and males. Future studies are needed to identify subgroups by tumor types and treatment regimens who are particularly at risk for COVID-19 infection and adverse outcomes.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454